Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

Abstract

Results from base-case and sensitivity analyses fell well below established benchmarks for cost-effectiveness in Sweden. The results, therefore, indicated that infliximab treatment for RA has provided good societal value for money in Swedish clinical practice, compared with a scenario of no biological treatment.